ストックスクリーナーアプリを入手
48.93
1.26%
0.61
アフターアワーズ：
48.68
-0.25
-0.51%
前日終値:
$48.32
開ける：
$48.6591
24時間の取引高:
1.52M
Relative Volume:
0.79
時価総額：
$4.66B
収益：
$38.34M
当期純損益:
$-488.30M
株価収益率:
-8.7687
EPS:
-5.5801
ネットキャッシュフロー:
$-303.14M
1週間 パフォーマンス:
+6.65%
1か月 パフォーマンス:
-11.52%
6か月 パフォーマンス:
-13.55%
1年 パフォーマンス:
+13.00%
1日の値動き範囲:
$47.39
$49.00
1週間の範囲:
$46.27
$50.63
52週間の値動き範囲:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Compare CRSP vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
48.93 | 4.60B | 38.34M | -488.30M | -303.14M | -5.5801 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-18 | 開始されました | JP Morgan | Overweight |
| 2025-02-14 | アップグレード | Evercore ISI | In-line → Outperform |
| 2025-02-12 | アップグレード | TD Cowen | Sell → Hold |
| 2025-02-03 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-06 | 繰り返されました | Needham | Buy |
| 2024-08-02 | 開始されました | Rodman & Renshaw | Buy |
| 2024-06-28 | 再開されました | Guggenheim | Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-11 | ダウングレード | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 開始されました | Mizuho | Buy |
| 2023-08-17 | アップグレード | Citigroup | Neutral → Buy |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-04-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-03-17 | 開始されました | Bryan Garnier | Buy |
| 2023-03-07 | 開始されました | Robert W. Baird | Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Underweight |
| 2022-08-09 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-06-14 | アップグレード | Citigroup | Sell → Neutral |
| 2021-04-21 | アップグレード | Jefferies | Hold → Buy |
| 2021-03-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-12-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2020-12-10 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-10 | 繰り返されました | Needham | Buy |
| 2020-12-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-07-28 | 繰り返されました | Needham | Buy |
| 2020-07-14 | 開始されました | SunTrust | Buy |
| 2020-06-15 | 繰り返されました | Canaccord Genuity | Buy |
| 2020-03-05 | 開始されました | Stifel | Hold |
| 2020-02-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-11-19 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 開始されました | Jefferies | Buy |
| 2019-07-26 | 開始されました | Canaccord Genuity | Buy |
| 2019-06-10 | 開始されました | ROTH Capital | Buy |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-14 | 開始されました | William Blair | Mkt Perform |
| 2019-01-28 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-22 | ダウングレード | Citigroup | Neutral → Sell |
すべてを表示
Crispr Therapeutics Ag (CRSP) 最新ニュース
CRISPR Therapeutics (NASDAQ:CRSP) Announces Quarterly Earnings Results - MarketBeat
Crispr Therapeutics earnings missed by $0.20, revenue fell short of estimates - Investing.com
Crispr Therapeutics (CRSP) Reports Lower-Than-Expected Q4 Revenue - GuruFocus
CRISPR Therapeutics AG SEC 10-K Report - TradingView
CRISPR Therapeutics Earnings Report: Q4 Overview - Benzinga
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Analysis: Unveiling A 69.80% Potential Upside - DirectorsTalk Interviews
Guidance Update: Is CRISPR Therapeutics AG backed by strong institutional buyingGlobal Markets & Daily Chart Pattern Signals - baoquankhu1.vn
Aug PreEarnings: Is CRISPR Therapeutics AG backed by strong institutional buyingCEO Change & Capital Protection Trading Alerts - baoquankhu1.vn
Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million - Yahoo Finance
Gene Editing Market Growth in Future Scope 2026-2033| CRISPR - openPR.com
Top CRISPR Companies for 2026 and How to Invest - The Motley Fool
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
CRISPR Therapeutics AG $CRSP Shares Bought by IQ EQ FUND MANAGEMENT IRELAND Ltd - MarketBeat
The Best Biotech Stocks to Buy - Morningstar
Citizens Maintains Outperform Rating On CRISPR Therapeutics (CRSP) Citing Undervalued Pipeline - Finviz
CRISPR Therapeutics AG (CRSP) Stock Analysis: Navigating The 64% Potential Upside - DirectorsTalk Interviews
CRISPR Therapeutics AG (CRSP) expected to beat earnings estimates: Should you buy? - MSN
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy? - Finviz
CRISPR Therapeutics (CRSP) Price Target Increased by 14.61% to 82.91 - Nasdaq
CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock? - TradingView
Pathway Capital Management LP Takes Position in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics (CRSP) to Release Quarterly Earnings on Tuesday - MarketBeat
Does CRISPR Therapeutics (CRSP) Pipeline Expansion And ARK’s Buying Redefine Its Long‑Term Narrative? - simplywall.st
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
Layoff Watch: Will CRISPR Therapeutics AG benefit from government policyQuarterly Trade Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
Why (CRSP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
CRISPR Therapeutics Milestones And ARK Backing Contrast With Valuation Gap - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Rating of "Hold" from Brokerages - MarketBeat
ARK’s Bigger CRISPR Therapeutics Stake Underscores Gene Editing Pipeline Story - simplywall.st
CRISPR Therapeutics (CRSP) Jumps 9.6% on Biotech Rally - MSN
Will CRISPR Therapeutics AG stock gain from lower inflationJuly 2025 Setups & Daily Profit Focused Stock Screening - mfd.ru
CRSP: Citizens Analyst Lowers Price Target to $80 | CRSP Stock N - GuruFocus
CRISPR Therapeutics (NASDAQ:CRSP) Given New $80.00 Price Target at Citizens Jmp - MarketBeat
CRISPR Therapeutics stock price target lowered to $80 by Citizens - Investing.com Nigeria
CRISPR Therapeutics CEO Share Sale Tests Confidence In Gene Editing Story - Sahm
ARK Investment Acquires Significant Stake in Crispr Therapeutics (CRSP) - GuruFocus
Forget AI Stocks: This Biotech Could Cure What AI Can't Touch - Finviz
Forget AI Stocks: This Biotech Could Cure What AI Can't Touch - The Motley Fool
What Does the Market Think About CRISPR Therapeutics AG? - Benzinga
BofA is Bullish on CRISPR Therapeutics AG (CRSP) - Insider Monkey
Assessing CRISPR Therapeutics (CRSP) Valuation After Recent Share Price Movements - Sahm
Why is CRISPR Therapeutics AG stock going downJuly 2025 Spike Watch & High Accuracy Swing Entry Alerts - mfd.ru
Top Executive Makes Bold Move With Fresh Crispr Therapeutics AG Stock Buy - TipRanks
CRISPR Therapeutics (NASDAQ:CRSP) Insider Purchases $49,703.68 in Stock - MarketBeat
CRISPR Therapeutics AG (CRSP) Stock Analysis: Unpacking the 52.71% Potential Upside for Investors - DirectorsTalk Interviews
Is CRISPR Therapeutics (CRSP) Still Attractive After A 67% Five Year Share Price Decline - Yahoo Finance
Assessing CRISPR Therapeutics’ Valuation As Recent Trading Puts CRSP Back In Focus - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why - sharewise.com
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
CRISPR Therapeutics (CRSP) Stock: Insider Sales Total $5.17 Million This Week - CoinCentral
Crispr Therapeutics Ag (CRSP) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):